Transcarent, a fast-growing health tech company led by former Livongo CEO Glen Tullman, has secured $126 million in Series D funding. The investment round was spearheaded by venture capital giants General Catalyst and 7wireVentures, where Tullman serves as a managing partner. With this funding, Transcarent aims to enhance its artificial intelligence capabilities, expand its business and explore potential acquisitions. To date, the company has raised approximately $450 million in funding.
Founded in 2020, Transcarent is among a growing number of emerging companies leveraging technology to improve care and reduce costs for organizations that offer health benefits to their employees. Unlike other healthcare navigation and virtual care firms that also aim to make care more affordable and accessible, Transcarent sets itself apart through its unique approach to healthcare management.
This article is exclusive to STAT+ subscribers. Subscribe now and gain unlimited access to award-winning journalism and exclusive events while transforming healthcare with cutting-edge technologies.
